UK Industry Urges Quick Adoption Of Accelerated Access Proposals As Brexit Clouds Gather
Executive Summary
UK review proposes key changes to the way that new medicines and medical technologies are identified, developed and adopted for use in the National Health Service, including an Accelerated Access Partnership of stakeholders that will manage the accelerated pathway to patients, a new government unit to discuss commercial arrangements, and a “transformative designation” to flag up products of greatest interest.
You may also be interested in...
Post-Brexit, Could A Sector Deal Boost UK Life Sciences?
Government proposals to provide a boost for the UK’s industrial base to counter the disruption likely from Brexit include “sector deals” between companies and government, new funds for innovation, and encouraging later-stage venture capital financing, all of which are likely already on the wish-list of companies in the life sciences sector.
BIA Says NHS Funding Changes Would Jeopardize Life Science Sector, As UK PM Announces ‘Hard’ Brexit
As prime minister Theresa May confirms that the UK is to leave the EU single market, the BioIndustry Association has warned that proposals by NICE and NHS England to change funding arrangements for innovative drugs risks impairing the competitiveness of the UK life sciences sector.
Denmark Planning To Impose Drug Stockpiling Obligations From July
A new bill is intended to address the increase in medicine supply problems in Denmark in recent years.